Treatment for Fetal Atrioventricular Block in Pregnant Individuals with Anti-SSA and Anti-SSB Antibodies

Treatment for Fetal Atrioventricular Block in Pregnant Individuals with Anti-SSA and Anti-SSB Antibodies: Evidence for this review will most likely be derived from observational studies due to the lack of randomized clinical trials on the condition. Several observational studies assessing the prevention of progression and treatment of fetal AVB have been published since the 2020 ACR clinical practice guideline but no recent comprehensive systematic review has synthesized this new evidence. With funding support from PCORI, the Evidence-based Practice Center Program will develop a new systematic evidence review on the treatment for fetal atrioventricular block in pregnant individuals who have anti-SSA and anti-SSB antibodies. Anti-SSA and anti-SSB antibodies are associated with several autoimmune conditions such as Sjogren's syndrome and systemic lupus erythematosus. This review will be used to develop clinical guidance and to identify evidence gaps for future research.